Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan-Mar;21(1):2773.
doi: 10.18549/PharmPract.2023.1.2773. Epub 2022 Jan 5.

The effects and safety of high dose vitamin D3 in hemodialysis patients

Adnane Guella  1 , Abduelmula R Abduelkarem  2 , Mohammed M Hassanein  3
Affiliations

The effects and safety of high dose vitamin D3 in hemodialysis patients

Adnane Guella et al. Pharm Pract (Granada). 2023 Jan-Mar.

Abstract

Background: Different studies have shown that hemodialysis patients require higher doses of Vitamin D3 (VD3) than the general population to achieve satisfactory replenishment. This study aims to assess the safety of such practice and its benefits on some of the parameters of Chronic Kidney Disease- Mineral and Bone Disorder (CKD-MBD).

Methods: A single-center clinical trial assessing the benefits of high dose VD3 in hemodialysis patients. The dose of VD3 (300,000 IU) was administered orally and monthly from April to December 2020 (9 months) at the dialysis unit. The data analyzed were blood levels of calcium, phosphorus, alkaline phosphatase, 25(OH)D, 1,25(OH)2D and intact parathyroid hormone (iPTH) done every three months.

Results: We could recruit a cohort of 23 patients. Blood levels of 25(OH)D increased significantly in 82.6% of the patients to above 30 ng/ml. A similar effect was observed with 1, 25(OH)2D levels. iPTH levels decreased significantly when levels of 25(OH)D exceeded 30ng/ml at the end of the nine months. Vitamin D serum levels were typically measured immediately before the next monthly dose was administered. Blood levels of calcium, phosphorus, and alkaline phosphatase were stable during the study period. No events of hypercalcemia were reported, and no patient discontinued the monthly VD3 supplementation.

Conclusion: Monthly administration of a high dose of VD3 over a long period of nine months in hemodialysis patients was found to be safe and beneficial in VD3 replenishment. It also allowed a significant decrease in iPTH levels. Further studies are warranted to identify the therapeutic target level of 25(OH)D in hemodialysis patients, allowing beneficial effects on iPTH.

Keywords: hemodialysis; hypercalcemia; parathyroid hormone; secondary hyperparathyroidism; vitamin D3.

PubMed Disclaimer

Conflict of interest statement

The authors certify that they have no affiliations with or involvement in any organization or entity with any financial or non-financial interest in the subject matter or materials discussed in this manuscript

Similar articles

See all similar articles

Cited by

References

    1. 1. Del Valle E, Negri AL, Aguirre C, et al. Prevalence of 25(OH) vitamin D insufficiency and deficiency in chronic kidney disease stage 5 patients on hemodialysis. Hemodial Int. 2007;11(3):315-21. http://dx.doi.org/10.1111/j.1542-4758.2007.00186.x - PubMed
    2. Del Valle E, Negri AL, Aguirre C, et al. Prevalence of 25(OH) vitamin D insufficiency and deficiency in chronic kidney disease stage 5 patients on hemodialysis. Hemodial Int. 2007;11(3):315–21. doi: 10.1111/j.1542-4758.2007.00186.x. - DOI - PubMed
    1. 2. Ravani P, Malberti F, Tripepi G, et al. Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int. 2009;75(1):88-95. http://dx.doi.org/10.1038/ki.2008.501 - PubMed
    2. Ravani P, Malberti F, Tripepi G, et al. Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int. 2009;75(1):88–95. doi: 10.1038/ki.2008.501. - DOI - PubMed
    1. 3. Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease:Results of the study to evaluate early kidney disease. Kidney Int. 2007;71(1):31-8. http://dx.doi.org/10.1038/sj.ki.5002009 - PubMed
    2. Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease:Results of the study to evaluate early kidney disease. Kidney Int. 2007;71(1):31–8. doi: 10.1038/sj.ki.5002009. - DOI - PubMed
    1. 4. Kim SM, Choi HJ, Lee JP, et al. Prevalence of vitamin D deficiency and effects of supplementation with cholecalciferol in patients with chronic kidney disease. J Ren Nutr. 2014;24(1):20-5. http://dx.doi.org/10.1053/j.jrn.2013.07.003 - PubMed
    2. Kim SM, Choi HJ, Lee JP, et al. Prevalence of vitamin D deficiency and effects of supplementation with cholecalciferol in patients with chronic kidney disease. J Ren Nutr. 2014;24(1):20–5. doi: 10.1053/j.jrn.2013.07.003. - DOI - PubMed
    1. 5. Wolf M, Shah A, Gutierrez O, et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int. 2007;72(8):1004-13. http://dx.doi.org/10.1038/sj.ki.5002451 - PubMed
    2. Wolf M, Shah A, Gutierrez O, et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int. 2007;72(8):1004–13. doi: 10.1038/sj.ki.5002451. - DOI - PubMed

LinkOut - more resources